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Objectives This study sought to investigate whether pregnancy-associated plasma protein-A (PAPP-A) is useful for risk as-
sessment in non–ST-segment elevation acute coronary syndrome (NSTE-ACS).
Background PAPP-A is a high molecular weight, zinc-binding metalloproteinase that is associated with vulnerable plaque and
may be a predictor of cardiovascular disease and mortality.
Methods We measured PAPP-A at baseline in 3,782 patients with non NSTE-ACS randomized to ranolazine or placebo in
the MERLIN–TIMI 36 (Metabolic Efficiency With Ranolazine for Less Ischemia in Non-ST Elevation Acute Coronary
Syndromes) trial and followed for an average of 1 year. A cut point of 6.0 IU/ml was chosen from pilot work in
this cohort.
Results PAPP-A 6.0 IU/ml at presentation was associated with higher rates of cardiovascular death (CVD) or myocar-
dial infarction (MI) at 30 days (7.4% vs. 3.7%, hazard ratio [HR]: 2.01; 95% confidence interval [CI]: 1.43 to
2.82; p  0.001) and at 1 year (14.9% vs. 9.7%, HR: 1.63; 95% CI: 1.29 to 2.05; p  0.001). PAPP-A was also
associated with higher rates of CVD (HR: 1.94; 95% CI: 1.07 to 3.52, p  0.027) and myocardial infarction (HR:
1.82; 95% CI: 1.22 to 2.71, p  0.003) individually at 30 days. There was no difference in the risk associated
with PAPP-A stratified by baseline cardiac troponin I [Accu-TnI 0.04 g/l], p interaction  0.87). After adjust-
ment for cardiac troponin I, ST-segment deviation, age, sex, diabetes, smoking, hypertension, and coronary ar-
tery disease, PAPP-A was independently associated with CVD/myocardial infarction at 30 days (adjusted HR:
1.62, 95% CI: 1.15 to 2.29; p  0.006) and 1 year (adjusted HR: 1.35, 95% CI: 1.07 to 1.71; p  0.012).
PAPP-A also improved the net reclassification for CVD/MI (p  0.003). There was no significant interaction with
ranolazine.
Conclusions PAPP-A was independently associated with recurrent cardiovascular events in patients with NSTE-ACS. This finding
supports PAPP-A as a candidate prognostic marker in patients with ACS and supports investigation of its therapeutic
implications. (J Am Coll Cardiol 2012;60:332–8) © 2012 by the American College of Cardiology Foundation
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July 24, 2012:332–8 PAPP-A and Outcomes in Patients With ACSMetalloproteinases have been implicated in the destabiliza-
tion of atherosclerotic plaque, specifically, degrading the
proteins that maintain the integrity of the protective fibrous
cap (1,2). Recognition of their biological proteolytic activity
has led to the hypothesis that metalloproteinases might be
markers of vulnerable or ruptured atherosclerotic plaque
(2,3). Pregnancy-associated plasma protein-A (PAPP-A) is
a high molecular weight, zinc-binding metalloproteinase
(1). Originally identified in pregnant women, in whom it is
produced in the placenta (4), PAPP-A is also found at lower
concentration in nonpregnant women and men. This en-
zyme has been shown to cleave insulin-like growth factor
binding protein-4 from insulin-like growth factor-1, an
important regulatory protein in cell proliferation and me-
tabolism (5).
The blood concentration of PAPP-A is increased in
patients with acute coronary syndromes (ACS), and
PAPP-A is present in vulnerable coronary plaque but not in
stable plaques (3,6). Two initial studies observed that
PAPP-A concentration is associated with recurrent isch-
emic events in patients with suspected ACS, including those
with undetectable troponin (3,7). However, subsequent
results have been mixed, and most of these studies were
performed in the setting of less sensitive previous-
generation assays for cardiac troponin (8).
We investigated whether PAPP-A, measured using a
highly sensitive assay developed to detect low concentra-
tions in nonpregnant individuals, would be useful in con-
junction with a contemporary sensitive assay for cardiac
troponin for assessing the risk of recurrent ischemic events
in patients presenting with non–ST-segment elevation
acute coronary syndromes (NSTE-ACS). In addition, we
evaluated the relationship of PAPP-A with other biomar-
kers representing potentially different pathobiological
processes.
Methods
Patient population. The MERLIN–TIMI 36 (Metabolic
Efficiency With Ranolazine for Less Ischemia in Non-ST
Elevation Acute Coronary Syndromes) trial enrolled 6,560
patients with NSTE-ACS and randomized them to treat-
ment with either ranolazine or placebo in a 1:1 ratio and
followed for a median of 348 days. The detailed entry
criteria have been reported (9,10) and are summarized in the
Online Appendix. The MERLIN–TIMI 36 trial, including
this substudy, was approved by the relevant institutional review
from CV Therapeutics and Sanofi-Aventis; grant support from Amgen, Critical
Diagnostics, Integrated Therapeutics, Millennium Pharmaceuticals, Novelo, and
Sanofi-Synthelab; and has served as a consultant for Beckman Coulter, Critical
Diagnostics, Gilead, Instrumentation Laboratories, Menarini, Merck & Co., Ortho-
Clinical Diagnostics, Roche, Sanofi-Aventis, Schering-Plough, and Siemens. All
other authors have reported that they have no relationships relevant to the contents of
this paper to disclose.Manuscript received December 29, 2011; revised manuscript received February 27,
2012, accepted April 2, 2012.boards at all participating centers.
Written informed consent was ob-
tained from all patients.
Biomarker testing. PAPP-A
was measured in serum in batch
(Active cPAPP-A ELISA, Beck-
man Coulter, Brea, California) by
personnel blinded to treatment al-
location and clinical events. Ana-
lytical sensitivity for the Active
cPAPP-A assay is 0.18 IU/ml,
ith total imprecision (cardiovas-
ular [CV]) of 10% and 6% at
oncentrations of 2 and 11 IU/
l, respectively. Troponin was
easured using the AccuTnI
Beckman Coulter using the 99th
ercentile reference limit (0.04g/l).
etails of sample collection and
ther biomarker testing are de-
cribed in the Online Appendix.
ndpoints. The primary end-
oint for this analysis was CV
eath or myocardial infarction
MI). All endpoints were adjudicated by an independent
linical endpoints committee, blinded to treatment alloca-
ion, according to definitions that were published previously
Online Appendix) (9,10).
tatistical methods. Baseline characteristics were com-
ared using the chi-square test for categorical variables and
he Wilcoxon rank sum test for continuous variables. Event
ates presented are Kaplan-Meier failure rates at 30 days and
2 months. The assessment of the relationship between
APP-A and outcome was performed using Cox regression.
nteraction testing was performed for PAPP-A concentra-
ion and heparin administration based on previous studies
emonstrating an interaction between heparin and PAPP-A
oncentration (11). Adjusted analyses included all elements
f a well-validated risk model in NSTE-ACS (Thrombol-
sis In Myocardial Infarction risk score) (12). There was no
nteraction with the randomized therapy, and therefore
reatment allocation was not included in the model.
A pilot study within a development set was performed to
evelop a prognostic cut point for validation and is de-
cribed in the Online Appendix. The optimized cut point
6.0 IU/ml) from the derivation set was then applied in
the validation set as well as in the entire cohort. The
increased discriminative value of PAPP-A in addition to
clinical predictors, and troponin was examined with the
method described by Harrell (13) to determine the net
reclassification improvement (NRI) (13). NRI was calcu-
lated for comparison of the clinical model with cardiac
troponin I (cTnI) alone and with PAPP-A using Har-
rell’s technique, as programmed in R, which evaluates the
change in estimated risk as a continuous variable and
Abbreviations
and Acronyms
ACS  acute coronary
syndrome(s)
BNP  B-type natriuretic
peptide
CI  confidence interval
cTnI  cardiac troponin I
CV  cardiovascular
CVD  cardiovascular
death
HR  hazard ratio
MI  myocardial infarction
MPO  myeloperoxidase
NRI  net reclassification
improvement
NSTE-ACS  non–ST-
segment elevation acute
coronary syndrome(s)
PAPP-A  pregnancy-
associated plasma
protein-Atherefore is not dependent on a previous categorization
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PAPP-A and Outcomes in Patients With ACS July 24, 2012:332–8(13). All analyses, unless otherwise specified, were per-
formed using STATA version 9.2 (StataCorp, College
Station, Texas).
Results
Baseline characteristics. PAPP-A was measured in all
available baseline serum samples (N  3,782). The baseline
characteristics of the study population are listed in Table 1.
Patients with a baseline concentration of PAPP-A 6.0
IU/ml (n  644, 17%) were older, more frequently male,
Baseline Characteristics by PAPP-A ConcentrationTable 1 Baseline Characteristics by PAPP-A Concentration
PAPP-A
<6.0 IU/ml
(n 3,138)
PAPP-A
>6.0 IU/ml
(n  644) p Value
Demographics
Age, 75 yrs, % 14 25 0.001
% Male 64 69 0.011
% White race 97 98 0.052
Weight, kg 82 (73–93) 80 (70–90) 0.001
Risk factors, %
Diabetes mellitus 34 27 0.002
Current smoker 25 22 0.067
History of hypertension 77 64 0.001
History of dysplipidemia 69 62 0.001
Previous myocardial infarction 36 36 0.79
Previous congestive heart failure 22 16 0.001
Previous PCI or CABG 26 26 0.87
Creatinine clearance 60 ml/min 19 26 0.001
Presentation, %
Index NSTEMI 46 61 0.001
Troponin I 0.04 58 73 0.001
TIMI risk score 3 75 76 0.19
ST-segment depression 1 mm 36 39 0.13
B-type natriuretic peptide,
80 pg/ml
42 50 0.001
High-sensitivity C-reactive protein
15
23 17 0.0047
Myeloperoxidase 670 pmol/l 35 65 0.001
Randomized treatment
Allocated to ranolazine, % 49 52 0.15
Values are % or median (interquartile range).
CABG  coronary artery bypass graft; IQR  interquartile range; NSTEMI  non–ST-segment
elevation myocardial infarction; PCI  percutaneous coronary intervention; PAPP-A  pregnancy-
associated plasma protein-A; TIMI  Thrombolysis In Myocardial Infarction.
PAPP-A Concentration and Cardiovascular OutcomesTable 2 PAPP-A Concentration and Cardiovascular Outcomes
30-Day Outcomes
PAPP-A
<6.0 IU/ml
(n  3,138), %
PAPP-A
>6.0 IU/ml
(n  644), % HR (95% CI)
CVD 1.2 2.3 1.94 (1.07–3.52)
MI 2.9 5.2 1.82 (1.22–2.71)
SRI 3.4 6.0 1.78 (1.23–2.58)
HF 1.8 2.4 1.29 (0.73–2.28)
CVD/MI 3.7 7.4 2.01 (1.43–2.82)
CVD/MI/SRI 6.9 11.9 1.78 (1.37–2.31)CI confidence interval; CVD cardiovascular death; HF heart failure; HR hazard ratio; MImyocardand more likely to have a creatinine clearance 60 ml/min;
however, they were less likely to have diabetes mellitus,
hypertension, or dysplipidemia.
Other correlates of PAPP-A. Patients with elevated base-
line levels were more likely to have had an index presenta-
tion of non–ST-segment elevation MI and to have a TIMI
risk score of 4. Nevertheless, PAPP-A was only weakly
correlated with the concentrations of cTnI (r  0.17),
B-type natriuretic peptide (BNP) (r  0.093), myeloperox-
idase (MPO) (r  0.39), and high-sensitivity C-reactive
protein (r  0.13) (all p  0.001). There was no
significant difference in left ventricular ejection fraction
(p  0.68) or severity of coronary artery disease (p  0.66)
among patients with and without elevated PAPP-A.
Cut-point determination. The derivation cohort of 543
patients was randomly selected for cut-point derivation.
Baseline characteristics and the distribution of PAPP-A
were similar between the derivation and validation sets and
are shown separately in Online Table 1, with the exception
of troponin elevation. A cut point of 6.0 IU/ml showed
the strongest relationship with CV death or MI and was
prospectively tested in the validation cohort (Online
Table 2). The prognostic performance of PAPP-A was
highly similar in the derivation and validation cohorts
(Online Tables 3 and 4), and therefore the results of the
overall cohort are presented from this point forward.
Unadjusted relationship between PAPP-A and CV outcomes.
In unadjusted analyses, patients with a baseline PAPP-A
6.0 IU/ml had an approximately 2-fold higher risk of
V death or MI at 30 days compared with those with
APP-A concentrations below the cut point (HR: 2.01; 95%
I: 1.43 to 2.82) (Table 2). The adverse CV risk associated
ith an elevated PAPP-A persisted through 12 months (HR:
.63; 95% CI: 1.29 to 2.05) (Fig. 1 and Table 2). Moreover,
atients with an elevated baseline PAPP-A had significantly
igher rates individually of 12-month recurrent ischemic
vents (MI, p  0.0049 and severe recurrent ischemia, p 
.032), as well as CV death (p  0.0028) compared with
atients with a baseline PAPP-A 6.0 IU/ml (Table 2).
here was no significant relationship between PAPP-A and
he risk of hospitalization for heart failure (Table 2).
12-Month Outcomes
ue
PAPP-A
<6.0 IU/ml
(n  3,138), %
PAPP-A
>6.0 IU/ml
(n  644), % HR (95% CI) p Value
7 4.0 6.9 1.68 (1.19–2.37) 0.0028
29 7.2 9.9 1.49 (1.13–1.98) 0.0049
19 10.3 13.2 1.31 (1.02–1.68) 0.032
3.8 4.6 1.19 (0.79–1.79) 0.42
1 9.7 14.9 1.63 (1.29–2.05) 0.001
1 18.1 23.2 1.38 (1.15–1.66) 0.001p Val
0.02
0.00
0.00
0.38
0.00
0.00ial infarction; PAPP-A pregnancy-associated plasma protein-A; SRI severe recurrent ischemia.
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July 24, 2012:332–8 PAPP-A and Outcomes in Patients With ACSApplication in conjunction with a sensitive troponin and
natriuretic peptide. The risk of CV death or MI associated
with baseline PAPP-A concentration was not modified by
troponin status as measured using a contemporary sensitive
assay both at 30 days (p interaction  0.93) and 12 months
(p interaction 0.87) (Fig. 2). A similar relationship between
PAPP-A and CV death or MI was seen among patients with
elevated BNP (Online Table 4 and Fig. 3).
Figure 1 CVD or MI by Baseline PAPP-A Concentration
Kaplan-Meier estimated cumulative incidence of cardiovascular death (CVD) or my
baseline pregnancy-associated plasma protein-A (PAPP-A) concentration at 6.0 IU
Figure 2 CVD or MI Baseline PAPP-A and cTnI Concentration
Kaplan-Meier estimated cumulative incidence of CVD or MI stratified by baseline P
and cardiac troponin I (cTnI) using the 99th percentile reference limit (0.04 g/l).Multivariable assessment of PAPP-A and CV outcomes.
When applied in conjunction with established clinical risk
predictors in ACS (age, sex, ST-segment deviation, diabetes,
smoking, hypertension, and history of coronary artery disease)
as well as established biomarkers (cTnI), PAPP-A was inde-
pendently associated with the risk of both 30-day CV
death/MI (adjusted HR: 1.62; 95% CI: 1.15 to 2.29; p 
0.006) and 30 day CV death, MI, or severe recurrent ischemia
l infarction (MI) stratified by
concentration at 6.0 IU/ml
abbreviations as in Figure 1.ocardia
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PAPP-A and Outcomes in Patients With ACS July 24, 2012:332–8(adjusted HR: 1.52; 95% CI: 1.16 to 1.98; p 0.002) (Fig. 4).
oreover, when other inflammatory biomarkers, MPO, and
igh-sensitivity C-reactive protein, and BNP were added to
he model in addition to TnI, only PAPP-A remained a
redictor of CV death or MI at 30 days (adjusted HR: 1.56;
5% CI: 1.09 to 2.24; p  0.015) and 1 year (adjusted HR:
.37; 95% CI: 1.07 to 1.75; p 0.011) (Fig. 5). There was no
Figure 3 CVD or MI at 30 Days by Baseline PAPP-A, BNP, and
Kaplan-Meier estimated cumulative incidence of CVD or MI at 30 days stratified by
99th percentile reference limit (0.04 g/l), and B-type natriuretic peptide (BNP) at
Figure 4 Adjusted Risk of Cardiovascular Events
at 30 Days and 1 Year
Adjusted hazard ratios for CVD or MI and CVD, MI, or severe recurrent isch-
emia (SRI) at both 30 days and 12 months. After adjusting for established clin-
ical predictors of outcome, patients who had a baseline PAPP-A concentration
6 IU/ml were consistently at higher risk of recurrent cardiovascular events
compared with patients who had baseline PAPP-A 6 IU/ml. Adjusted for ele-
ments of Thrombolysis In Myocardial Infarction risk score (age, multiple risk
factors, known coronary disease, aspirin use, severe angina, cTnI using the
99th percentile reference limit [0.04 g/l] and ST-segment deviation), and sex.
Abbreviations as in Figure 1.rsignificant interaction between PAPP-A and heparin use for
CV death/MI or CV death, MI, or severe recurrent ischemia
at 30 days or 1 year (p  0.65 for each interaction).
Reclassification of risk. The incremental improvement in
risk stratification beyond clinical risk predictors was evalu-
ated using NRI as a measure of reclassification. The
addition of PAPP-A dichotomized at 6.0 IU/ml signifi-
antly improved reclassification for cardiovascular death
CVD)/MI (p  0.003) and for CVD/MI/severe recurrent
schemia (p  0.021) at 12 months. Furthermore, when
TnI was added to clinical predictors, the NRI remained
ignificant for both CVD/MI (p  0.0028) and for CVD/
I/severe recurrent ischemia (p  0.021). In contrast to
eclassification, there was no significant improvement in the
-statistic for CVD/MI by adding PAPP-A to clinical
redictors and TnI (0.706 vs. 0.709, p  0.23).
iscussion
e found that an elevated PAPP-A concentration in patients
ith NSTE-ACS identified individuals at significantly higher
hort and long-term risk of adverse CV events when used
ndependently and in conjunction with clinical characteristics
nd contemporary sensitive troponin and natriuretic peptide
ssays. Importantly, PAPP-A was predictive of the risk of
ecurrent MI rather than new or worsening heart failure.
onsistent with the hypothesized pathobiology, these findings
upport PAPP-A specifically as a candidate marker of risk of
ecurrent atherothrombosis and differentiates PAPP-A from
ther novel markers such as natriuretic peptides and MPO,
hich are markers of all-cause mortality and heart failure
ut show variable association with recurrent ischemic events
14–16).
linical and research implications. Hospitalization for
Concentration
-A concentration at 6.0 IU/ml, cTnI using the
/ml at baseline. Abbreviations as in Figures 1 and 2.cTnI
PAPP
80 pgecurrent ischemic events occurs in as many as 1 in every 5
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July 24, 2012:332–8 PAPP-A and Outcomes in Patients With ACSpatients during the first year after NSTE-ACS (17). Al-
hough clinical models for the prediction of CV mortality
fter ACS have been developed and are used clinically,
rediction of recurrent ischemic events with similarly high
iscrimination has been difficult (18), as evident by the
ignificant decrement in the c-statistic of the TIMI risk
core for patients with NSTE-ACS when predicting MI
0.66) versus mortality (0.74) (12) and for the Global
egistry of Adverse Coronary Events score when predicting
eath or MI (0.70) compared with death alone (0.82) (19).
ardiac troponin is strongly and reproducibly associated
ith the risk of recurrent ischemic events after ACS.
owever, other newer established or emerging biomarkers
ave proven to have stronger associations with heart failure
vents (20). As we have shown previously in this population,
NP is an independent predictor of death and heart failure;
owever, it is not strongly predictive of recurrent ischemic
vents (21). In this context, our findings with PAPP-A are
ntriguing, both for its potential role as a clinical risk
redictor and for therapeutic guidance.
Smaller previous studies have found mixed results regard-
ng the association between PAPP-A and recurrent isch-
mic events independent of TnI or in patients with unde-
Figure 5 Adjusted Risk of CVD/MI With
Concurrent Assessment of Novel Biomarkers
Adjusted hazard ratios for CVD or MI at both 30 days and 12 months by base-
line PAPP-A, myeloperoxidase (MPO), C-reactive protein (CRP), and BNP concen-
tration. After adjusting for established clinical predictors and established
prognostic markers, patients who had a baseline PAPP-A concentration
6 IU/ml were consistently at higher risk of recurrent cardiovascular events
compared with patients who had baseline PAPP-A 6 IU/ml. Adjusted for ele-
ments of Thrombolysis In Myocardial Infarction risk score (age, multiple risk
factors, known coronary disease, aspirin use, severe angina, cTnI using the
99th percentile reference limit [0.04 g/l] and ST-segment deviation), sex,
PAPPA 6 IU/ml, MPO 670 pmol/l, high-sensitivity CRP 15 mg/l, and
BNP 80 pg/ml. Abbreviations as in Figures 1 and 3.ectable TnI (3,7). Lund et al. (7) found that increasing vAPP-A was an independent predictor of future ischemic
vents in 136 consecutive patients presenting to the emer-
ency department with suspected ACS found to be cTnI
egative. Heeschen et al. (22) found similar results in a
arger cohort of 644 patients with chest pain. These studies,
owever, used insensitive TnI assays by current standards or
ut points above those currently recommended, leading to
ecommendations for assessment using contemporary assays
nd cut points (8,23). Notably, our current study prospec-
ively demonstrated a significant relationship between
APP-A and CV death or recurrent ischemic events in
,782 patients in conjunction with a contemporary sensitive
ssay for cTnI. Moreover, our large sample size adds
ubstantially, more than doubling, the previous experience
ith PAPP-A for risk assessment and also permitted us to
uild a separate derivation set for development and internal
alidation of a prognostic decision limit.
The potential complementary nature of PAPP-A to other
iomarkers that reflect distinct pathways underlying the
evelopment of recurrent events is further supported by the
eak correlation between PAPP-A and markers of myone-
rosis, hemodynamic stress, and even nonspecific markers of
nflammation. Although each of these dimensions of perfor-
ance that we observed with PAPP-A are interesting, further
esearch is required to establish clear therapeutic ties (24).
Although the prognostic implications of increased
APP-A appear reproducible and a plausible role in plaque
estabilization exists, the precise pathways and contribu-
ion, if any, of PAPP-A relative to other metalloproteinases
n plaque instability have yet to be definitively established.
ur findings support additional mechanistic investigation
f these pathways. Alternative interpretations of the asso-
iation of PAPP-A and outcomes have also been proposed
ncluding a protective effect mediated through insulin-like
rowth factor-1 that is elicited in response to ischemic
njury (6,25). Such an investigation is also likely to be
aluable in elucidating the potential for PAPP-A as a
herapeutic target (26). Previous work has shown that
APP-A concentrations are not influenced by statin ther-
py, at least in stable patients with hypercholesterolemia
27), and the current analysis nested in MERLIN–TIMI 36
rial found no interaction with ranolazine.
tudy limitations. This study was limited to patients
elected for participation in a clinical trial who presented
ith suspected ACS and had samples available for analysis.
s such, these results do not address the question of prognostic
ignificance in the broader group of patients presenting with
ontraumatic chest pain, including those patients with symp-
oms atypical of myocardial ischemia or presenting with other
cute illnesses that may be inflammatory in nature. Al-
hough samples were handled using standardized proce-
ures, it is possible that pre-analytical issues (i.e., storage)
ould have affected the stability of PAPP-A. Any such effect
ould be expected to have led us to underestimate the
agnitude of the risk relationship. In addition, externalalidation of our proposed cut point in separate datasets
H
m
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PAPP-A and Outcomes in Patients With ACS July 24, 2012:332–8would be valuable. Finally, we used an available contempo-
rary sensitive troponin assay in this investigation, and
different results might be observed if repeated using a
third-generation highly sensitive assay.
Conclusions
PAPP-A was independently associated with the short- and
long-term risk of CV death and recurrent ischemic events in
patients with NSTE-ACS, along with clinical predictors
and cTnI. The relationship with severe recurrent ischemic
events differentiates PAPP-A from other novel markers that
reliably predict only all-cause mortality and heart failure.
Our findings add to emerging evidence supporting the
metalloproteinase PAPP-A as a candidate prognostic
marker of recurrent ischemia and CV death in patients with
ACS and supports continued investigation of its potential
therapeutic implications.
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